Icotrokinra’s NEJM Data Reveals the Quiet Shift in How UC Trials Get Designed and Approved
J&J's icotrokinra hit every UC endpoint in NEJM's Oct 2026 data, and the trial design choices behind that success...
FDA Guidance
Base Editing’s Decade of Promise Meets Its Regulatory Reckoning
Base editing reached human trials, but the FDA's April 2026 NGS safety draft guidance reveals how far the regulatory...
Clinical Prediction Models Are Breaking Trials and Nobody Is Requiring a Fix
Only 12% of ~4,000 clinical prediction model studies share code, per Nature Medicine. FDA and NIH mandates exist, but...
Platform Trials Are Rewriting the Rules of Evidence. Regulators Haven’t Caught Up.
Adaptive platform trials like REMAP-CAP enrolled 4,869 critically ill COVID patients across 300+ sites, but FDA's master protocol guidance...
Platform Trials Are Rewriting the Rules of Evidence Generation. Regulators Haven’t Caught Up.
Adaptive platform trials like RECOVERY and REMAP-CAP are transforming infectious disease research, but FDA and EMA guidance still lags...
The FDA Just Handed Psychedelic Drug Sponsors a Framework. Now the Hard Part Starts.
FDA finalized its psychedelic drug guidance July 14, 2026. COMPASS, Usona, and MAPS now face blinding failures, DEA barriers,...
What FDA’s July 2026 Psychedelic Drug Guidance Actually Says About Trial Design
FDA's finalized psychedelic guidance rewrites the rules on blinding, informed consent, and session monitoring, and the NEJM's September 2026...
The Validation Accords: Clinical Trials Are About to Learn What “Validated AI” Actually Means
Nature Medicine's Validation Accords push for a generative AI consensus framework, and expose a regulatory gap that could invalidate...
The Algorithm Passed Every Benchmark. The Patients Didn’t Notice.
A landmark Nature Medicine RCT found AI improved clinician decisions but not patient outcomes, exposing the fatal flaw in...
Early Termination No Longer Means Failure. It Means the Trial Was Working.
Early trial termination once signaled collapse. Now it signals design sophistication, and regulators, sponsors, and CROs need a new...